Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial.

Kelly, Peter; Weimar, Christian; Lemmens, Robin; Murphy, Sean; Purroy, Francisco; Arsovska, Anita; Bornstein, Natan M; Czlonkowska, Anna; Fischer, Urs; Fonseca, Ana Catarina; Forbes, John; Hill, Michael D; Jatuzis, Dalius; Kõrv, Janika; Kruuse, Christina; Mikulik, Robert; J Nederkoorn, Paul; O'Donnell, Martin; Sandercock, Peter; Tanne, David; ... (2021). Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial. European stroke journal, 6(2), pp. 222-228. Sage 10.1177/2396987320972566

[img] Text
Kelly__2021__Colchicine_for_prevention_of_vascular_inflammation.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (946kB) | Request a copy


Inflammation contributes to unstable atherosclerotic plaque and stroke. In randomised trials in patients with coronary disease, canukinumab (an interleukin-1B antagonist) and colchicine (a tubulin inhibitor with pleiotropic anti-inflammatory effects) reduced recurrent vascular events.Hypothesis: Anti-inflammatory therapy with low-dose colchicine plus usual care will reduce recurrent vascular events in patients with non-severe, non-cardioembolic stroke and TIA compared with usual care alone.


CONVINCE is a multi-centre international (in 17 countries) Prospective, Randomised Open-label, Blinded-Endpoint assessment (PROBE) controlled Phase 3 clinical trial in 3154 participants. The intervention is colchicine 0.5 mg/day and usual care versus usual care alone (antiplatelet, lipid-lowering, antihypertensive treatment, lifestyle advice). Included patients are at least 40 years, with non-severe ischaemic stroke (modified Rankin score ≤3) or high-risk TIA (ABCD2 > 3, or positive DWI, or cranio-cervical artery stenosis) within 72 hours-28 days of randomisation, with qualifying stroke/TIA most likely caused by large artery stenosis, lacunar disease, or cryptogenic embolism. Exclusions are stroke/TIA caused by cardio-embolism or other defined cause (e.g. dissection), contra-indication to colchicine (including potential drug interactions), or incapacity for participation in a clinical trial. The anticipated median follow-up will be 36 months. The primary analysis will be by intention-to-treat.


The primary outcome is time to first recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation with unstable angina (non-fatal or fatal).


CONVINCE will provide high-quality randomised data on the efficacy and safety of anti-inflammatory therapy with colchicine for secondary prevention after stroke.


First-patient first-visit was December 2016. Recruitment to complete in 2021, follow-up to complete in 2023.

Item Type:

Journal Article (Further Contribution)


04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Fischer, Urs (A)


600 Technology > 610 Medicine & health








Chantal Kottler

Date Deposited:

30 Sep 2021 15:55

Last Modified:

04 Feb 2023 23:37

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

Ischaemic stroke colchicine inflammation randomised controlled trial




Actions (login required)

Edit item Edit item
Provide Feedback